New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 10, 2014
07:06 EDTFATEFate Therapeutics announces issuance of U.S. patent for Stem Cell Cultures
Fate Therapeutics announced that the U.S. Patent and Trademark Office has issued Patent No. 8,691,573 entitled "Stem Cell Cultures." The newly issued patent claims a class of small molecule inhibitors of Rho-associated kinase, or ROCK, that are crucial to the therapeutic application of human induced pluripotent stem cells, or hiPSCs. Modulators belonging to the patented class have been shown to be necessary for the high-throughput derivation of transgene-free hiPSCs, and for the maintenance, survival and genomic stability of hiPSCs in culture. Fate Therapeutics holds an exclusive license from The Scripps Research Institute to the patent in all commercial fields.
News For FATE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 25, 2015
07:16 EDTFATEPiper Jaffray and the Alliance for Regenerative Medicine co-host conference
3rd Annual Regenerative Medicine Investor Day is being held in New York on March 25 with webcasted company presentations to begin at 8 am; not all company presentations may be webcasted. Webcast Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use